<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752802</url>
  </required_header>
  <id_info>
    <org_study_id>TP-6495</org_study_id>
    <nct_id>NCT02752802</nct_id>
  </id_info>
  <brief_title>DyeVert System RCT</brief_title>
  <official_title>Single Site Randomized Control Trial Evaluating the DyeVert System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osprey Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osprey Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the amount of contrast media (CM) saved using the
      DyeVert system in diagnostic angiographic procedures compared to a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, parallel group, single center clinical evaluation of the
      DyeVert System. Subjects undergoing a diagnostic coronary angiogram procedure with a 5 French
      catheter are eligible to participate in this study. The treatment group will use the DyeVert
      System.

      The trial will be conducted at one center, located in Germany. A sample size of 96 evaluable
      subjects will provide a sufficient number of samples to evaluate the primary objectives.

      Randomization will occur following confirmation that the subject meets the
      inclusion/exclusion criteria and has signed an informed consent. Subjects that are
      anticipated to be a diagnostic only procedure, but end up being an ad-hoc PCI, can still
      remain enrolled in the trial. If a subject proceeds to a PCI, data will only be collected
      through the diagnostic portion of the case.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group.</measure>
    <time_frame>All data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
    <description>DyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Quality of Angiographic Images Between Groups</measure>
    <time_frame>AlAll data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
    <description>To assess the adequacy of the image quality. The proportion of images in which contrast opacification is deemed sufficient to evaluate the desired anatomical structures adequately will be compared between the DyeVert and control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Incidence of Serious Adverse Device Effect for Subjects Treated With the DyeVert System During the Procedure.</measure>
    <time_frame>All data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
    <description>To assess the incidence of Serious Adverse Device Effect for subjects treated with the DyeVert System during the procedure for treatment subjects only.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Coronary Angiography</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will include standard of care for diagnostic coronary angiograms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diagnostic Coronary Angiogram</intervention_name>
    <description>Diagnostic angiographic procedure with the use of the DyeVert System.</description>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is indicated for a diagnostic coronary angiogram procedure with a 5 French
             catheter only.

          2. The subject is ≥ 18 years of age

          3. The subject is willing and able to provide appropriate informed consent.

        Exclusion Criteria:

          1. Subject is undergoing a STEMI procedure

          2. Subject has previously been diagnosed with anomalous coronary anatomy

          3. Subject has previously underwent coronary artery bypass grafting

          4. Subject has severe peripheral artery disease at access site

          5. Subject is having a staged PCI

          6. The subject is female and currently pregnant

          7. In the investigator's opinion, the subject is not considered to be a suitable
             candidate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Desch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Schleswig-Holstein, Lubeck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Brown JR, Solomon RJ, Sarnak MJ, McCullough PA, Splaine ME, Davies L, Ross CS, Dauerman HL, Stender JL, Conley SM, Robb JF, Chaisson K, Boss R, Lambert P, Goldberg DJ, Lucier D, Fedele FA, Kellett MA, Horton S, Phillips WJ, Downs C, Wiseman A, MacKenzie TA, Malenka DJ; Northern New England Cardiovascular Disease Study Group. Reducing contrast-induced acute kidney injury using a regional multicenter quality improvement intervention. Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):693-700. doi: 10.1161/CIRCOUTCOMES.114.000903. Epub 2014 Jul 29.</citation>
    <PMID>25074372</PMID>
  </reference>
  <reference>
    <citation>Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000 Nov 1;36(5):1542-8.</citation>
    <PMID>11079656</PMID>
  </reference>
  <reference>
    <citation>Klein LW, Sheldon MW, Brinker J, Mixon TA, Skelding K, Strunk AO, Tommaso CL, Weiner B, Bailey SR, Uretsky B, Kern M, Laskey W; Interventional Committee of the Society for Cardiovascular Angiography and Interventions. The use of radiographic contrast media during PCI: a focused review: a position statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):728-46. doi: 10.1002/ccd.22113. Review.</citation>
    <PMID>19830793</PMID>
  </reference>
  <reference>
    <citation>Lameire N, Kellum JA; KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care. 2013 Feb 4;17(1):205. doi: 10.1186/cc11455. Review.</citation>
    <PMID>23394215</PMID>
  </reference>
  <reference>
    <citation>Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996 May 15;275(19):1489-94.</citation>
    <PMID>8622223</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <results_first_submitted>November 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2017</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast Media</keyword>
  <keyword>Angiography</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>The control group will include standard of care for diagnostic coronary angiograms.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Contrast Volume Not Collected</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The control group will include standard of care for diagnostic coronary angiograms.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="13.6"/>
                    <measurement group_id="B2" value="66.2" spread="12.8"/>
                    <measurement group_id="B3" value="67.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group.</title>
        <description>DyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)</description>
        <time_frame>All data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The control group will include standard of care for diagnostic coronary angiograms.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group.</title>
          <description>DyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" spread="13.1"/>
                    <measurement group_id="O2" value="62.5" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Quality of Angiographic Images Between Groups</title>
        <description>To assess the adequacy of the image quality. The proportion of images in which contrast opacification is deemed sufficient to evaluate the desired anatomical structures adequately will be compared between the DyeVert and control groups.</description>
        <time_frame>AlAll data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The control group will include standard of care for diagnostic coronary angiograms.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
          </group>
          <group group_id="O2">
            <title>Treatment</title>
            <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Quality of Angiographic Images Between Groups</title>
          <description>To assess the adequacy of the image quality. The proportion of images in which contrast opacification is deemed sufficient to evaluate the desired anatomical structures adequately will be compared between the DyeVert and control groups.</description>
          <units>Images</units>
          <param>Count of Units</param>
          <units_analyzed>Images</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Images</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Incidence of Serious Adverse Device Effect for Subjects Treated With the DyeVert System During the Procedure.</title>
        <description>To assess the incidence of Serious Adverse Device Effect for subjects treated with the DyeVert System during the procedure for treatment subjects only.</description>
        <time_frame>All data will be collected on the day of the procedure, over an average of 12 hours.</time_frame>
        <population>Only treatments subjects were analyzed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Incidence of Serious Adverse Device Effect for Subjects Treated With the DyeVert System During the Procedure.</title>
          <description>To assess the incidence of Serious Adverse Device Effect for subjects treated with the DyeVert System during the procedure for treatment subjects only.</description>
          <population>Only treatments subjects were analyzed for this endpoint.</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At point of discharge from index procedure, approximetly 12 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>The control group will include standard of care for diagnostic coronary angiograms.
Diagnostic Coronary Angiogram: Diagnostic angiographic procedure with the use of the DyeVert System.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Extended Hospital Stay</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Adverse Events</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michele Shepard, Vice President of Clinical Affairs</name_or_title>
      <organization>Osprey Medical, Inc</organization>
      <phone>952-955-8236</phone>
      <email>mshepard@ospreymed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

